Main Research Findings

Two studies investigated the safety and tolerability of dolutegravir and lamivudine. 1 was a retrospective study on 151 Korean adults living with HIV (PLWH), divided into treatment-naïve and switching groups. was a real-world evaluation of abacavir/dolutegravir/lamivudine in an incarcerated population.

Reasons for Side Effects

Side effects from dolutegravir and lamivudine can occur due to various factors, including the drug's properties, individual body characteristics, and interactions with other medications.

Common Side Effects

Gastrointestinal

In the 1 study, 5 participants reported mild side effects, such as indigestion, constipation, diarrhea, and fatigue, but no patient discontinued treatment during the follow-up period.

Kidney Function

The 1 study noted slightly elevated creatinine levels in both groups compared to baseline.

Side Effect Management

Gastrointestinal Side Effects

If you experience gastrointestinal side effects like indigestion, constipation, or diarrhea, consult your doctor to discuss appropriate management strategies. Options may include dietary changes or medications.

Kidney Function Side Effects

If you have concerns about kidney function, talk to your doctor and undergo regular checkups.

Comparison between Studies

Similarities

Both studies indicated that dolutegravir and lamivudine combinations are generally safe and well-tolerated. Neither study reported serious side effects.

Differences

The 1 study was a retrospective analysis of Korean PLWH, divided into treatment-naïve and switching groups. In contrast, focused on a real-world evaluation of incarcerated individuals. These differences in study populations and designs may have influenced the results.

Real-World Application Notes

While dolutegravir and lamivudine combinations offer a viable treatment option for HIV, they may not be suitable for everyone. It is crucial to consult with your doctor, consider the risk of side effects, and make informed decisions about the best treatment plan for your individual circumstances.

Limitations of Current Research

Both studies were relatively small in size and involved specific populations. Therefore, the results may not be generalizable to all PLWH. More research is needed.

Future Research Directions

Larger-scale studies involving more diverse populations, including different races and ethnicities, are essential. Research focusing on the long-term safety and effectiveness of dolutegravir and lamivudine combinations is also crucial.

Conclusion

These research findings suggest that dolutegravir and lamivudine combinations hold potential as effective treatment options for HIV. However, it is essential to consult with your doctor, consider the risk of side effects, and choose an appropriate treatment plan based on your individual circumstances. Remember, continuous research is vital for understanding the long-term implications of these medications.